NCT02969720 (FESIME) is a NA clinical trial of Phytosterols in Metabolic Syndrome x, sponsored by Universidad de los Andes, Chile.

Who is sponsoring NCT02969720?

NCT02969720 is sponsored by Universidad de los Andes, Chile.

What drugs are being tested in NCT02969720?

Interventions in NCT02969720: Phytosterols, Titanium Dioxide.

What condition does NCT02969720 study?

NCT02969720 studies Metabolic Syndrome x.

Is NCT02969720 still recruiting?

NCT02969720 is currently completed. Last updated 17 March 2020.

Last reviewed 2020-03-17 · How we verify

NCT02969720: FESIME

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Therapeutic Efficacy of Phytosterols on Metabolic Syndrome

Completed NA Last updated 17 March 2020

What this trial tests

NA trial testing Phytosterols in Metabolic Syndrome x in 220 participants. Completed in 27 November 2018.

Timeline

8 January 2018

Primary endpoint
27 November 2018

27 November 2018

Quick facts

Lead sponsor	Universidad de los Andes, Chile
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	220
Start date	8 January 2018
Primary completion	27 November 2018
Estimated completion	27 November 2018
Sites	1 location across Chile

Drugs / interventions tested

Phytosterols
Titanium Dioxide (TITANIUM DIOXIDE) — full drug profile →

Conditions studied

Metabolic Syndrome x — all drugs for Metabolic Syndrome x →

Sponsor

Universidad de los Andes, Chile — full company profile →

Who can join

Adults 18 to 65, any sex, with Metabolic Syndrome x. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective is to evaluate therapeutic efficacy of 2 grams nano-phytosterols daily supplemention on diagnosis criteria of metabolic syndrome.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of Daily Consumption of an Aqueous Dispersion of Free-Phytosterols Nanoparticles on Individuals with Metabolic Syndrome: A Randomised, Double-Blind, Placebo-Controlled Clinical Trial.
Palmeiro-Silva YK, Aravena RI, Ossio L, Parro Fluxa J. · · 2020 · cited 4× · PMID 32785036 · DOI 10.3390/nu12082392

Verify or expand the search:

Other Universidad de los Andes, Chile trials

Trials by the same sponsor.

NCT07334288 — Retrolaminar Analgesia for LuMbar Surgery · NA · recruiting
NCT07063914 — Stratified-Care School-Based Intervention for Adolescent Suicidal Ideation · NA · recruiting
NCT07001202 — Acceptability and Feasibility of Reframe-IT+U for Suicidality in University Students. · NA · not yet recruiting
NCT06630143 — The Effectiveness of Combined Virtual and Clinical Simulation in Midwifery Students · NA · completed
NCT07034235 — Effect of Wet and Overwet Dentin on the Clinical Performance of Two Universal Adhesive Systems · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02969720 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Universidad de los Andes, Chile
Last refreshed: 17 March 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02969720.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing